Belgium
Imcyse SA, headquartered in Belgium, is a pioneering player in the biopharmaceutical sector, advancing a novel class of immunotherapies to combat severe autoimmune diseases. Founded in 2011 as a spin-off from the Catholic University of Leuven (KULeuven), the company has carved a niche with its cutting-edge Imotope™ technology. These modified synthetic peptides are engineered to specifically interrupt improper immune responses, offering a way to prevent and address conditions that currently lack effective treatments.
The company's lead product, IMCY-0098, is currently in Phase 2 clinical trials targeting early onset type 1 diabetes. This innovative approach positions Imcyse to potentially revolutionize treatment paradigms in the autoimmune sector without weakening patients' immune defenses.
Boasting a robust intellectual property portfolio, Imcyse received a €21.30M Series B investment in February 2021 from prominent investors including Belgian Federal Investment, Noshaq, Biogenosis, Epimède, Pfizer, S.R.I.W., and KU Leuven.
